ResMed Inc. (NYSE:RMD) Shares Purchased by Lbp Am Sa

LBP AM SA lifted its stake in shares of ResMed Inc. (NYSE:RMD - Free Report) by 136.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,818 shares of the medical equipment provider's stock after acquiring an additional 3,357 shares during the period. LBP AM SA's holdings in ResMed were worth $1,331,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. True Wealth Design LLC grew its position in ResMed by 2,200.0% in the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock valued at $28,000 after acquiring an additional 110 shares in the last quarter. OFI Invest Asset Management acquired a new position in ResMed in the 4th quarter valued at about $39,000. BankPlus Trust Department acquired a new position in ResMed in the 4th quarter valued at about $44,000. Rosenberg Matthew Hamilton acquired a new position in ResMed in the 4th quarter valued at about $54,000. Finally, SBI Securities Co. Ltd. acquired a new position in shares of ResMed during the fourth quarter worth about $67,000. Hedge funds and other institutional investors own 54.98% of the company's stock.

Insider Transactions at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the sale, the director now owns 77,218 shares in the company, valued at $18,695,249.98. This represents a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the company's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the sale, the chief executive officer now owns 455,472 shares of the company's stock, valued at $107,842,105.44. This trade represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,940 shares of company stock worth $9,164,385 over the last 90 days. 0.71% of the stock is currently owned by insiders.

Remove Ads

Analyst Ratings Changes

A number of equities analysts have recently commented on RMD shares. Piper Sandler boosted their price objective on ResMed from $252.00 to $260.00 and gave the stock a "neutral" rating in a research report on Friday, January 31st. StockNews.com raised ResMed from a "hold" rating to a "buy" rating in a research report on Saturday, March 15th. UBS Group raised ResMed from a "hold" rating to a "strong-buy" rating in a research report on Friday, January 31st. The Goldman Sachs Group started coverage on ResMed in a research report on Thursday, January 16th. They set a "buy" rating for the company. Finally, Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $246.83.

ResMed Stock Performance

NYSE RMD traded down $0.92 on Thursday, reaching $221.13. The stock had a trading volume of 671,111 shares, compared to its average volume of 974,118. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. ResMed Inc. has a 12-month low of $172.19 and a 12-month high of $263.05. The business's 50-day moving average price is $235.48 and its 200 day moving average price is $239.36. The stock has a market cap of $32.48 billion, a P/E ratio of 26.11, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, equities analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 13th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.96%. The ex-dividend date is Thursday, February 13th. ResMed's dividend payout ratio (DPR) is presently 25.03%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.